Pfizer appeals on anti-kickback case; Chinese rare disease biotech enlists UW to research Duchenne gene therapies
Last month, a judge told Pfizer that the pharma giant cannot pay out-of-pocket costs for Medicare patients to buy the company’s $225,000-a-year heart drug tafamidis …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
